Safety and Effectiveness of Tirzepatide (Mounjaro) for Weight Loss

Tirzepatide (Mounjaro), recently approved by the FDA, is a novel medication initially developed for type 2 diabetes. It also shows exceptional weight loss results by acting on both GIP and GLP-1 receptors, regulating appetite and blood sugar levels.

In a landmark study published in the New England Journal of Medicine, patients lost an average of 15–20% of body weight over 72 weeks—results comparable to some bariatric surgeries.

When used under medical supervision, tirzepatide is generally safe. Common side effects include nausea, diarrhea, or constipation, which tend to be mild and temporary.

It is not recommended for individuals with a family history of medullary thyroid carcinoma or pancreatitis. A full clinical assessment is essential before starting treatment.

Tirzepatide offers a promising non-surgical alternative for those seeking sustainable weight loss, particularly when paired with lifestyle and dietary changes.

Source: NEJM 2022 – Tirzepatide for Obesity